Timothy E. Morris
Timothy E. Morris has served as the Chief Operating Officer and Chief Financial Officer of Humanigen, Inc. (Nasdaq: HGEN) since August 2020. Mr. Morris previously served on the Board of Directors as an Independent Director and Chairman of the Audit Committee from July 2016 to July 2020. Mr. Morris currently serves as a Non-Executive Director for DBV Technologies S.A. (Nasdaq: DBVT, Euronext: DBV – ISIN: FR0010417345). Mr. Morris has 36 years of professional finance and accounting experience, including 22 years as Chief Financial Officer with public biotechnology companies (IOVA, ACRX, VVUS, QCOR). During his career he has raised over $2 billion in equity and convertible securities for seven companies, including four offerings for IOVA with over $1 billion in proceeds. Prior to Humanigen, Mr. Morris was CFO at Iovance where he oversaw an increase in market cap from $550 million to $4.2 billion (7x increase). In addition, he served as the financial lead for Iovance’s state of the art $85 million cell therapy manufacturing facility in Philadelphia. He has extensive deal experience with over 90 transactions and combined value over $5 billion. Mr. Morris has been part of executive teams that were successful in the approval of 3 NDAs and 1 MAA. He is a CPA (inactive) and started his career from Chico State with Ernst & Young in Silicon Valley.